Advances in clinical characteristics and prognostic factors of amyotrophic lateral sclerosis

doi:10.11958/20230475

Abstract

Abstract:

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease with marked clinical heterogeneity, with an extremely variable time course from diagnosis to death or severe disability. The heterogeneity of ALS hinders the accurate prediction of endpoints and the development of novel therapies. Further identification of ALS prognostic factors will help to build a good survival prediction model, accurately predict survival time, and promote the development of ALS treatment.

Key words: amyotrophic lateral sclerosis, prognosis, prediction model

CLC Number:

R746.4

References 34

[1]	KIERNAN M C, VUCIC S, TALBOT K, et al. Improving clinical trial outcomes in amyotrophic lateral sclerosis[J]. Nat Rev Neurol, 2021, 17(2):104-118. doi:10.1038/s41582-020-00434-z.
[2]	BAUCKNEHT M, LAI R, MICELI A, et al. Spinal cord hypermetabolism extends to skeletal muscle in amyotrophic lateral sclerosis:a computational approach to [18F]-fluorodeoxyglucose PET/CT images[J]. EJNMMI Res, 2020, 10(1):23. doi:10.1186/s13550-020-0607-5.
[3]	GAO M, LIU N, LI X M, et al. Epidemiology and factors predicting survival of amyotrophic lateral sclerosis in a large Chinese cohort[J]. Chin Med J(Engl), 2021, 134(18):2231-2236. doi:10.1097/CM9.0000000000001679.
[4]	SUN Q, HUO Y, BAI J, et al. Characteristics of late-onset amyotrophic lateral sclerosis in a Chinese cohort[J]. Neurodegener Dis, 2021, 21(1/2):24-29. doi:10.1159/000519002.
[5]	HUANG S, ZHENG M, LIN J, et al. Natural history and remarkable psychiatric state of late-onset amyotrophic lateral sclerosis in China[J]. Acta Neurol Scand, 2022, 146(1):24-33. doi:10.1111/ane.13598.
[6]	LI J Y, SUN X H, CAI Z Y, et al. Correlation of weight and body composition with disease progression rate in patients with amyotrophic lateral sclerosis[J]. Sci Rep, 2022, 12(1):13292. doi:10.1038/s41598-022-16229-9.
[7]	SUN Q H, LI Y R, LAN W J, et al. Prognostic value of time to generalization in 71 Chinese patients with sporadic amyotrophic lateral sclerosis[J]. Chin Med J(Engl), 2019, 132(9):1023-1027. doi: 10.1097/CM9.0000000000000200.
[8]	HE Z, SUN B, FENG F, et al. Time of symptoms beyond the bulbar region predicts survival in bulbar onset amyotrophic lateral sclerosis[J]. Neurol Sci, 2022, 43(3):1817-1822. doi:10.1007/s10072-021-05556-w.
[9]	RICHARDS D, MORREN J A, PIORO E P. Time to diagnosis and factors affecting diagnostic delay in amyotrophic lateral sclerosis[J]. J Neurol Sci, 2020, 417:117054. doi:10.1016/j.jns.2020.117054.
[10]	SUN C, FOURNIER C N, YE S, et al. Chinese validation of the Rasch-built overall amyotrophic lateral sclerosis disability scale[J]. Eur J Neurol, 2021, 28(6):1876-1883. doi:10.1111/ene.14811.
[11]	FOURNIER C N, BEDLACK R, QUINN C, et al. Development and validation of the Rasch-built overall amyotrophic lateral sclerosis disability scale(ROADS)[J]. JAMA Neurol, 2020, 77(4):480-488. doi:10.1001/jamaneurol.2019.4490.
[12]	PINTO S, de CARVALHO M. SVC is a marker of respiratory decline function, similar to FVC, in patients with ALS[J]. Front Neurol, 2019, 10:109. doi:10.3389/fneur.2019.00109.
[13]	ENACHE I, PISTEA C, FLEURY M, et al. Ability of pulmonary function decline to predict death in amyotrophic lateral sclerosis patients[J]. Amyotroph Lateral Scler Frontotemporal Degener, 2017, 18(7/8):511-518. doi:10.1080/21678421.2017.1353097.
[14]	HUANG X, DU C, YANG Q, et al. Comparison of slow and forced vital capacity on ability to evaluate respiratory function in bulbar-involved amyotrophic lateral sclerosis[J]. Front Neurol, 2022, 13:938256. doi:10.3389/fneur.2022.938256.
[15]	HUYNH W, AHMED R, MAHONEY C J, et al. The impact of cognitive and behavioral impairment in amyotrophic lateral sclerosis[J]. Expert Rev Neurother, 2020, 20(3):281-293. doi:10.1080/14737175.2020.1727740.
[16]	XU Z, ALRUWAILI A, HENDERSON R D, et al. Screening for cognitive and behavioural impairment in amyotrophic lateral sclerosis:Frequency of abnormality and effect on survival[J]. J Neurol Sci, 2017, 376:16-23. doi:10.1016/j.jns.2017.02.061.
[17]	MURDOCK B J, ZHOU T, KASHLAN S R, et al. Correlation of peripheral immunity with rapid amyotrophic lateral sclerosis progression[J]. JAMA Neurol, 2017, 74(12):1446-1454. doi:10.1001/jamaneurol.2017.2255.
[18]	CUI C, INGRE C, YIN L, et al. Correlation between leukocyte phenotypes and prognosis of amyotrophic lateral sclerosis[J]. Elife, 2022, 11:e74065. doi:10.7554/eLife.74065.
[19]	INGRE C, CHEN L, ZHAN Y, et al. Lipids, apolipoproteins, and prognosis of amyotrophic lateral sclerosis[J]. Neurology, 2020, 94(17): e1835-e1844. doi:10.1212/WNL.0000000000009322.
[20]	HOLDOM C J, JANSE V M M, VAN EIJK R, et al. Venous creatinine as a biomarker for loss of fat-free mass and disease progression in patients with amyotrophic lateral sclerosis[J]. Eur J Neurol, 2021, 28(11):3615-3625. doi:10.1111/ene.15003.
[21]	GUO Q F, HU W, XU L Q, et al. Decreased serum creatinine levels predict short survival in amyotrophic lateral sclerosis[J]. Ann Clin Transl Neurol, 2021, 8(2):448-455. doi:10.1002/acn3.51299.
[22]	CHENG Y, CHEN Y, SHANG H. Aberrations of biochemical indicators in amyotrophic lateral sclerosis:a systematic review and meta-analysis[J]. Transl Neurodegener, 2021, 10(1):3. doi:10.1186/s40035-020-00228-9.
[23]	de CARVALHO M, DENGLER R, EISEN A, et al. Electrodiagnostic criteria for diagnosis of ALS[J]. Clin Neurophysiol, 2008, 119(3):497-503. doi:10.1016/j.clinph.2007.09.143.
[24]	SATO M, NAKAMURA T, NAGASHIMA K, et al. Prolonged distal latency of the median motor nerve is associated with poor prognosis in amyotrophic lateral sclerosis[J]. Neurol Res, 2021, 43(3):191-198. doi:10.1080/01616412.2020.1834291.
[25]	IMAI E, NAKAMURA T, ATSUTA N, et al. A nerve conduction study predicts the prognosis of sporadic amyotrophic lateral sclerosis[J]. J Neurol, 2020, 267(9):2524-2532. doi:10.1007/s00415-020-09858-5.
[26]	FILECCIA E, De PASQUA S, RIZZO G, et al. Denervation findings on EMG in amyotrophic lateral sclerosis and correlation with prognostic milestones:Data from a retrospective study[J]. Clin Neurophysiol, 2020, 131(8):2017-2022. doi:10.1016/j.clinph.2020.04.161.
[27]	VACCHIANO V, DI STASI V, RIZZO G, et al. Prognostic value of EMG genioglossus involvement in amyotrophic lateral sclerosis[J]. Clin Neurophysiol, 2021, 132(10):2416-2421. doi:10.1016/j.clinph.2021.07.011.
[28]	COLOMBO E, DORETTI A, SCHEVEGER F, et al. Correlation between clinical phenotype and electromyographic parameters in amyotrophic lateral sclerosis[J]. J Neurol, 2023, 270(1):511-518. doi:10.1007/s00415-022-11404-4.
[29]	FERRARO P M, CABONA C, MEO G, et al. Age at symptom onset influences cortical thinning distribution and survival in amyotrophic lateral sclerosis[J]. Neuroradiology, 2021, 63(9):1481-1487. doi:10.1007/s00234-021-02681-3.
[30]	MILELLA G, INTRONA A, GHIRELLI A, et al. Medulla oblongata volume as a promising predictor of survival in amyotrophic lateral sclerosis[J]. Neuroimage Clin, 2022, 34:103015. doi:10.1016/j.nicl.2022.103015.
[31]	RIZZO G, MARLIANI A F, BATTAGLIA S, et al. Diagnostic and prognostic value of conventional brain MRI in the clinical work-up of patients with amyotrophic lateral sclerosis[J]. J Clin Med, 2020, 9(8):2538. doi:10.3390/jcm9082538.
[32]	TAVAZZI E, DABERDAKU S, ZANDONA A, et al. Predicting functional impairment trajectories in amyotrophic lateral sclerosis:a probabilistic, multifactorial model of disease progression[J]. J Neurol, 2022, 269(7):3858-3878. doi:10.1007/s00415-022-11022-0.
[33]	ACKRIVO J, HANSEN-FLASCHEN J, WILEYTO E P, et al. Development of a prognostic model of respiratory insufficiency or death in amyotrophic lateral sclerosis[J]. Eur Respir J, 2019, 53(4):1802237. doi:10.1183/13993003.02237-2018.
[34]	GROLLEMUND V, CHAT G L, SECCHI-BUHOUR M S, et al. Development and validation of a 1-year survival prognosis estimation model for amyotrophic lateral sclerosis using manifold learning algorithm UMAP[J]. Sci Rep, 2020, 10(1):13378. doi:10.1038/s41598-020-70125-8.